HOX genes are essential regulators of development in all multicellular organisms, including humans. We have previously shown that HOXA10 is expressed in the developing uterus and later in the adult human endometrium. HOX genes regulate endometrial development in response to sex steroids. Here, we demonstrate that HOXA10 is expressed in the myometrium as well. In situ hybridization reveals abundant HOXA10 expression, and Northern analysis demonstrates differential HOX gene expression in the myometrium throughout the menstrual cycle. HOXA10 expression decreases in the midsecretory phase, coinciding with high serum progesterone levels. Treatment of primary myometrial cell cultures with progesterone decreases HOXA10 expression in vitro-paralleling the expression seen in vivo. Despite the presence of progesterone receptors in the endometrium and myometrium, HOXA10 is differentially regulated in each tissue by progesterone. HOXA10 expression is induced in the stroma and decreased in the myometrium by progesterone.
H
OMEOBOX GENES ENCODE evolutionarily conserved transcription factors that are essential for development. These genes contain a common sequence element of 183 bp, known as the homeobox, that was first identified in the fruit fly, Drosophila melanogaster (1) . Mutations in homeotic genes of Drosophila generally cause one body segment to develop with characteristics of another segment (2) . Mammalian species have at least 39 HOX genes that each have parallel and overlapping expression domains and are arranged in four clusters termed HOX A, B, C, and D (3). These genes are highly conserved between insects and vertebrates, including humans-structurally, functionally, and in their chromosomal organization (4) . The genes that are located 5Ј in the clusters are expressed more posteriorly, whereas the more 3Ј located genes are expressed progressively in more anterior regions (3) . The homeodomain proteins are transcriptional transregulators; they activate or repress the expression of target genes (5) .
The expression of HOX genes in their designated location along the paramesonephric duct leads to the development of adult structures (6) . Four genes of the HOXA cluster (HOXA9, HOXA10, HOXA11, and HOXA13) are expressed in the developing reproductive system. HOXA9 is expressed in the primordia of the fallopian tube whereas HOXA10 is expressed in the developing uterus. HOXA11 is expressed in the lower uterine segment and cervix, and HOXA13 is expressed in the developing upper vagina (6) .
In addition to regulating the development of the uterus, HOXA10 expression is important for endometrial development, allowing uterine receptivity to implantation. Female mice with a targeted disruption of Hoxa10 are viable but have uterine factor infertility (7) . These mice ovulate normally, however, they are unable to support implantation. When HOXA10 (Ϫ/Ϫ) embryos are transferred to a wildtype surrogate implantation occurs successfully. Wild-type embryos are unable to implant in a HOXA10-deficient uterus. Blocking maternal HOXA10 expression in the uterus of wild-type mice similarly blocks implantation, demonstrating the necessity of adult expression (8) . We have previously shown that HOXA10 is expressed in both glandular and stromal cells in the human endometrium (9) . Menstrual cycle stage-dependent expression of HOXA10 suggests a role for HOX genes in the regulation of endometrial development in human (9) . There is a dramatic rise in HOXA10 expression in the midsecretory phase, the time of implantation. The aberrant HOXA10 expression seen in patients with infertility confirms its function in human implantation (10) . Progesterone directly regulates the expression of HOXA10 in the adult endometrium. This action is independent of new protein synthesis (9) .
Although endometrial HOX gene expression is well characterized, the expression of HOX genes in the myometrium and possible regulation by sex steroids has not previously been investigated. The endometrium is composed of glandular epithelium and stromal cells. The underlying myometrium is primarily composed of smooth muscle cells. Other than the vasculature, all components of uterine tissue express estrogen receptor (ER) and progesterone receptor (PR) (11) .
During the menstrual cycle glandular epithelium and stroma undergo characteristic cyclic changes. ER and PR expression varies during the menstrual cycle in the endometrium and myometrium (11) . In both these tissues ER and PR expression increases throughout the proliferative phase. However, ER and PR rapidly decline in the endometrial glands during secretory phase whereas the myometrium and endometrial stroma continue to express high levels of PR (11) . How these changes in sex steroid receptors impact on differential tissuespecific gene expression is an active area of investigation.
Here, we demonstrate HOXA10 expression in the human myometrium and show that sex steroids regulate this expression in the adult uterus. Despite the fact that ER and PR expression patterns are similar in the endometrial stroma and myometrium, HOX gene regulation by sex steroids in the myometrium is different from that in the endometrium. We also postulate that HOXA10 may have a developmental role in the myometrium.
Materials and Methods

Cell culture
Myometrial samples were obtained from two different normal cycling women in the late proliferative phase. The tissue was finely minced with scissors and scalpel in HBSS. The minced tissue was then supplemented with myodigest containing DNase (0.1 mg/mL, 1500 U/mg), HEPES (25 mm), penicillin (200 U/mL), streptomycin (200 g/mL), and collagenase (1 mg/mL, 15 U/mg) and was incubated at 37 C with agitation for 4 h. The cells were separated by filtration through a wire sieve with 73-m diameter pores. The myometrial cells were pelleted, washed, and suspended in DMEM F12 supplemented with FBS (10%) and antibiotic-antimycotic preparation (1%). The cells were passaged once and grown to confluence. Confluent monolayers were maintained in serum-free media for 48 h and subsequently treated with 17␤-estradiol (5 ϫ 10 Ϫ8 m) or medroxyprogesterone acetate (1 ϫ 10 Ϫ8 m). ER and PR status was verified by enzyme-linked immunosorbent assay according to the manufacturer's instructions (Abbot Laboratories, Wiesbaden, Germany).
In situ hybridization
In situ hybridization was performed with both sense and antisense 33 P-labeled riboprobes. The myometrium was fixed in 4% paraformaldehyde, cryoprotected in 30% sucrose, and then embedded in OCT compound (Miles Laboratories, Elkhart, IN). Ten micromolar frozen sections were obtained and mounted on Vectabound-coated slides (Vector Laboratories, Inc. Burlingame, CA). Before use sections were treated with 0.2 m HCl, Pronase (0.16 mg/mL), and 0.026 m acetic anhydride and were then dehydrated. Tissue sections were hybridized overnight with 3 ϫ 10 6 cpm of each probe in 0.25 m NaCl, 0.01 m Tris-HCl (pH 7.5), 0.01 m NaPO 4 (pH 6.8), 5 mm EDTA, Ficoll 400 (0.02%), polyvinylpyrolidone (0.02%), BSA fraction V (0.02%), 50% formamide, 12.5% dextran sulfate, yeast total RNA (tRNA) (1.25 mg/mL), and 10 mm dithiothreitol. Hybridization was performed in a humidified chamber for 16 h at 50 C. Slides were treated with RNase at 37 C and were then washed for 16 h in 0.25 m NaCl, 0.01 m Tris-HCl (pH 7.5), 0.01 m NaPO 4 (pH 6.8), 5 mm EDTA, Ficoll 400 (0.02%), polyvinylpyrolidone (0.02%), BSA fraction V (0.02%), and 50% formamide. Slides were dehydrated, dried, and dipped K5D emulsion (Ilford Limited, Moberley, Cheshire, UK). Exposure was carried out at 4 C for 7-12 days, and slides were developed with Kodak d-19 (Eastman Kodak Co., Rochester, NY). Slides were counterstained with hematoxylin and eosin. Representative bright-field photomicrographs were taken at ϫ20 on a microscope (Olympus Corp., Lake Success, NY) with Kodak Ektachrome film (Eastman Kodak Co.).
Tissue collection
Twenty-seven normally cycling women of reproductive age provided samples under an approved Institutional Human Investigations Committee protocol. The mean age of the patients was 44 yr (median, 45; range, 34 -50). The patients underwent hysterectomy for symptomatic leiomyomata (n ϭ 20), pelvic pain (n ϭ 4), and menometrorrhagia (n ϭ 3). Women taking hormonally active medications other than GnRH agonists were excluded from this study. The four patients on GnRH agonists demonstrated atrophic myometrium, as specified in the results. The tissue was immediately placed in liquid nitrogen and stored at Ϫ72 C. Menstrual cycle dating was determined from menstrual cycle history and confirmed histologically using the criteria of Noyes et al. (12) . The myometrial samples were obtained in the late proliferative phase of the menstrual cycle for myometrial tissue culture.
Northern blot analysis
RNA from tissue or cells was isolated using Trizol (Life Technologies, Inc., Carlsbad, CA) pursuant to the manufacturer's guidelines. Total RNA (40 -50 g) was size fractionated on 1% agarose/0.66 m formaldehyde gel and transferred to nylon membranes. Membranes were hybridized with a [ 512 ]P-labeled riboprobe as described below. The hybridization was performed 3 h at 68 C in Perfecthyb buffer (Sigma, St. Louis, MO), 0.2% tRNA, and [ 512 ]P-labeled riboprobe at 2 ϫ 10 6 cpm/mL. The filter was washed twice at 60 C for 20 min in 0.1ϫ SSC and 0.1% SDS. X-Omat AR (Eastman Kodak Co.) was exposed overnight at Ϫ70 C.
Probe preparation
Plasmids used for probe preparation were a generous gift from E. Boncinnelli (Scientific Institute San Raffaele, Milan, Italy) and have been well characterized by this group and others (6, 9) . PGEM plasmids containing 103 bp of the 3Ј untranslated region of human HOXA10 were linearized with EcoRI or HindIII (New England Biolabs, Inc., Beverly, MA), ethanol precipitated, and used as template for generating riboprobes. Radiolabeled RNA probes were generated by in vitro transcription using a Riboprobe Kit (Promega Corp., Madison, WI). Antisense probes were generated using RNA polymerase SP6 and labeled with [ 33 ]P-UTP or [ 32 ]P-UTP for in situ hybridization or Northern analysis, respectively (Amersham Pharmacia Biotech, Uppsala, Sweden). Sense probes were generated using T7 RNA polymerase and labeled with [ 33 ]P-UTP.
Statistical analysis
The autoradiographic bands were quantified using a laser densitometer. Each HOXA10 band was normalized to the value obtained from the same lane hybridized to glyceraldehyde-3-phosphate dehydrogenase (G3PDH). Data were analyzed using ANOVA. Statistical significance was defined as P less than 0.05.
Results
HOXA10 is expressed in the human myometrium
HOXA10 expression has been previously shown in the endometrial stroma and glands (9) . In this study, we examined HOXA10 gene expression in the myometrium. Uterine tissues from 27 reproductive age women undergoing hysterectomy at the Yale New Haven Hospital were obtained under an approved Human Investigations Committee protocol. No preoperative medical therapy was used within 3 months before surgery. HOXA10 expression was localized within the myometrium using in situ hybridization. Myometrial sections were hybridized with antisense 33 P-labeled riboprobes consisting of the 3Ј untranslated region of HOXA10. Figure 1A shows a representative bright-field photomicrograph of the myometrium hybridized to the antisense HOXA10 riboprobe. Abundant hybridization is demonstrated by the presence of silver grains over virtually every myocyte in all sections examined. Sections were obtained from multiple anatomic locations within the uterus. Hybrid-ization of uterus to a sense control probe showed no significant signal (Fig. 1B) .
Myometrial HOXA10 expression varies throughout the menstrual cycle
HOXA10 shows a menstrual cycle stage-dependent expression pattern in the endometrium (9) . To determine whether HOXA10 expression varies in the myometrium through the menstrual cycle, uterine tissue was collected from normally cycling reproductive age women. The 27 specimens were divided into approximately equal groups corresponding to atrophic (inactive), to proliferative, and to early, mid, and late luteal stages based on endometrial dating (12) . Northern blot analysis with an antisense [ 32 ]P-labeled riboprobe specific to the 3Ј untranslated region of HOXA10 was performed. Significant levels of HOXA10 expression are seen in the myometrium throughout the menstrual cycle, as demonstrated in Fig. 2A . After the hybridization to a control probe (G3PDH) densitometric analysis was performed on each sample. HOXA10 expression was normalized to G3PDH (Fig. 2B) .
There was no statistical difference in HOXA10 expression between the stages of the proliferative phase: early, mid, and late. HOXA10 messenger RNA (mRNA) levels in the midsecretory phase are approximately 30% of levels observed during the proliferative phase. This decrease was statistically significant by ANOVA (P Ͻ 0.05). Expression in the mid and late secretory phase was not significantly different at the power of this study (P ϭ 0.06). These results indicate that myometrial HOXA10 expression varies during the menstrual cycle inversely to HOXA10 expression in the endometrium. Myometrial HOXA10 expression markedly decreases in the midsecretory phase.
Hormonal regulation of HOXA10 in primary myometrial cell culture
Previously, we have demonstrated that HOXA10 expression is regulated by sex steroids in the human endometrium (9) . To determine the effects of sex steroids on HOXA10 expression in the myometrium, we used primary myometrial cell cultures obtained from the proliferative phase of the menstrual cycle. After cultured cells reached confluence, serum-free media were used for 48 h; cells were then treated with either physiologic 17␤-estradiol (5 ϫ 10 Ϫ8 ) or medroxyprogesterone acetate (1 ϫ 10 Ϫ8 ). After 24 h, RNA was extracted and Northern blot analysis was performed. Estrogen, similar to its effect in the endometrium, stimulated HOXA10 expression in myometrial cells (Fig. 3A) . Treatment with progestin showed a differential effect on HOXA10 expression in myometrial cells from that exerted in the endometrium. HOXA10 expression was significantly decreased by Error bars are SEM *, Statistically significant difference from the proliferative phase. Atrophic phase, n ϭ 4; proliferative phase, n ϭ 8; early secretory phase, n ϭ 4; midsecretory phase, n ϭ 5; late secretory phase, n ϭ 6.
progestin after 24 h of treatment (Fig. 3A) . Densitometry was performed and HOXA10 expression was normalized to G3PDH. The results of independent cell cultures were pooled, and statistical analysis was performed. As demonstrated in Fig. 3B, estradiol increased HOXA10 expression to approximately twice that of control cells. Progestin decreased HOXA10 expression by 50%. Estradiol and progestin together decreased HOXA10 expression by amount similar to that of progestin alone. Figure 4 shows the time-dependent expression of HOXA10 in response to 17␤-estradiol, progestin, or 17␤-estradiol plus progestin treatment. HOXA10 expression is increased by estradiol at 24 h (data not shown); progestin treatment decreases HOXA10 expression by 24 h compared with untreated primary myometrial cell cultures, and the expression remains repressed at 72 h. By 120 h the effect of progesterone is no longer detectable. The maximal effect is produced at 24 h after treatment. To maintain PR expression and assure that PR depletion was not responsible for the reversal of the progesterone effect at 72 h, cells were concomitantly treated with estradiol. Progestin plus estradiol treatment results in an initial increase in HOXA10 expression, but a decrease similar to that observed with progestin treatment alone was obtained after 24 h. These findings are consistent with the decreased HOXA10 expression observed in the myometrium in the midsecretory phase, coinciding with the time of increased circulating progesterone. HOXA10 is negatively regulated by progesterone in the myometrium.
Discussion
Expression of HOXA10 in the myometrium
HOX genes have been identified in the developing mü llerian system, and their expression persists in the adult female reproductive tract (6). HOXA10 is expressed in both glandular and stromal cells of the endometrium that undergo cyclic developmental changes in response to circulating sex steroids. HOXA10 expression is observed in the proliferative phase when estrogen is the predominant steroid hormone affecting the uterus. Endometrial HOXA10 expression dramatically increases in the midsecretory phase at the time when progesterone levels rise rapidly (9) .
Here, we demonstrate that HOXA10 is expressed in human myometrium and that this expression also has a menstrual cycle-stage-dependent pattern. However, levels of myometrial HOXA10 expression are lowest in the midsecretory phase, at the same time as the endometrium shows high levels of HOXA10 expression. It is known that ovarian steroids play an important role in regulating the growth patterns of human myometrium. Kawaguchi et al. (13) showed that myometrial cell cultures show active growth in the presence of estrogen and progesterone. They later demonstrated that progesterone increases mitotic activity of human myometrium in the secretory phase (14) . HOXA10 may mediate these effects on the myometrium. HOX genes are known to regulate both differentiation and cell growth (15) . Differential HOXA10 expression is likely to contribute to myometrial growth and differentiation.
During the secretory phase, the endometrium is developing to a state of receptivity. Whereas the endometrium shows differentiation and maturation in response to high levels of HOXA10 in preparation for implantation, the role of the myometrium in the nonpregnant uterus is unknown. HOXA10 expression increases to regulate endometrial differentiation to allow implantation; the simultaneous decrease in myometrial HOXA10 levels may allow dedifferentiation of this tissue and thereby allow growth in response to pregnancy. Diminished expression of HOXA10 may cause increased growth, resulting in the increased mitosis seen in the secretory phase. The reciprocally coordinated HOXA10 gene expression in the endometrium and myometrium may reflect their different roles in preparation for pregnancydifferentiation vs. dedifferentiation and growth.
Sex steroid regulation of HOXA10 in the myometrium
We have previously shown that estrogen and progesterone regulate HOX gene expression in the endometrium. ER and PR expression has been characterized in endometrial stroma and glands as well as in the myometrium (11) . ER expression is synchronized in all three tissues demonstrating maximum receptor numbers in the proliferative phase and rapid decline in the secretory phase. PR expression similarly increases throughout the proliferative phase within the endometrium and myometrium, however, myometrium and stroma do not show decreased PR expression in the secretory phase. There is a profound decline in PR expression only in glandular epithelium during the secretory phase.
The effects of estrogen and progesterone are mediated by these nuclear receptors. ER and PR transduce steroidal signals into the specific changes in gene expression that give rise to uterine morphogenic responses (16) . HOXA10 expression is induced by progesterone in the stroma (9) . Despite the expression of PR in the myometrium, we have shown HOXA10 expression decreases in this tissue in the secretory phase. Our data indicate that progesterone specifically down-regulates HOXA10 expression in myometrial cells. Despite the presence of PR in both tissues, we demonstrated the opposite effects of progesterone on HOXA10 expression in the myometrium and stroma.
Steroid hormones direct finely regulated patterns of gene expression that coordinate processes involved in development, differentiation, and reproduction. Although these events are relatively well characterized on a physiologic level, the molecular mechanisms by which these hormones and their receptors regulate the transcription of target genes are only partly understood (17) . Transcriptional control is a multistep process that involves coactivators, corepressors, and their associated proteins (18) . It has recently been shown that steroid receptor coactivators (SRCs) are restricted in a tissue cell type-specific manner (19) . Whereas disruption of the SRC-3 gene in mice results in delayed puberty and abnormal reproductive function, SRC-1 mutations cause partial resistance to multiple hormones, including estrogen, progesterone, androgen, and thyroid hormone (20) . These coactivators could explain the differential expression of HOXA10 in different reproductive tissue in response to progesterone. Although 17␤-estradiol and diethylstilbestrol both bind to the same domain of the ER, they differentially activate HOX expression and likely interact with different coactivators (21) . It is possible that differential coactivator expression between the myometrium and endometrium underlies the differential expression of HOX genes in response to progesterone as well. We are currently investigating the possibility that these coregulator proteins are positive or negative regulators of HOX gene expression.
